[Therapeutic effect of recombinant interferon alpha-2b on hemorrhagic fever with renal syndrome].

To study the therapeutic effect of recombinant interferon alpha-2b(rIFN alpha-2b) on cases of hemorrhagic fever with renal syndrome(HFRS) in early stage, 146 cases of HFRS in feverish stage and within five days of onset were randomly divided into two groups: the treatment and the control, each group included 73 cases. The control group was given the traditional combined therapy with a predominance of balanced solution, the treatment group was given rIFN alpha-2b 1 x 10(6)U per day, i.m., for three days. The treatment group showed much better effects in improving the viremia, the clinical conditions, skipping phases, restoring kidney function and platelet account, decreasing complications than the control group (P < 0.05). All the patients of the treatment group recovered, and four patients of the control group died, accounting for 5.47%. No side-effect resulting from rIFN alpha-2b was found. Administration of rIFN alpha-2b to patients with HFRS within five days of onset could lighten the organ lesions, shorten the course of disease and raise the curative rate.